Hepatic Encephalopathy

• Ammonia hypothesis and nitrogen metabolism dysregulation: Ammonia (NH₃) is a primary neurotoxin in HE, produced from bacterial urease activity in the colon, amino acid deamination, and renal glutaminase. In normal physiology, ammonia is metabolized primarily by the liver through the urea cycle (conversion to urea for excretion) and glutamine synthesis via glutamine synthetase. In hepatic dysfunction, decreased hepatic ammonia clearance combined with portosystemic shunting allows ammonia to enter systemic circulation and cross the blood-brain barrier (particularly the lipid-soluble NH₃ form; pKa 9.25). Within astrocytes, ammonia is incorporated into glutamate via glutamate dehydrogenase to form glutamine, which accumulates to osmotically significant levels. This osmotic stress causes astrocytic swelling and cerebral edema, contributing to altered mental status. Additionally, ammonia directly inhibits the Na⁺-K⁺-ATPase pump and impairs neurotransmitter synthesis, leading to decreased GABA metabolism and increased dopamine catabolism (reducing GABAergic inhibition). The ammonia-glutamine cycle triggers oxidative stress through mitochondrial dysfunction and reactive oxygen species (ROS) generation, with particular vulnerability of astrocytes. Ammonemia correlates imperfectly with HE severity (some patients tolerate high ammonia levels without symptoms while others become encephalopathic at modest elevations), indicating multifactorial pathogenesis.

• GABAergic neurotransmission enhancement and manganese accumulation: In cirrhosis, there is increased production and reduced metabolism of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter. Enhanced GABAergic tone contributes to sedation, confusion, and lethargy. This occurs through decreased hepatic GABA uptake and metabolism, increased bacterial production of GABA, and upregulation of GABA receptors in the brain. Additionally, benzodiazepine-like substances (endogenous ligands that enhance GABA receptor function) accumulate in cirrhosis. Manganese (Mn²⁺) accumulation is particularly important: manganese is normally excreted in bile, so cholestatic liver disease leads to accumulation preferentially in the basal ganglia and brainstem. MRI imaging demonstrates T1-weighted hyperintensities in these regions (though not specific for active HE). Manganese causes direct neurotoxicity through oxidative stress and mitochondrial dysfunction, and facilitates ammonia neurotoxicity through impaired astrocytic ammonia metabolism (manganese inhibits glutamine synthetase activity and promotes ammonia-induced astrocytic swelling).

• Inflammatory cytokines, oxidative stress, and impaired cerebral autoregulation: Cirrhosis is characterized by systemic inflammation with elevated TNF-α, IL-6, and IL-1β, which breach the blood-brain barrier and directly impair neuronal function. Lipopolysaccharides (LPS) from gram-negative bacteria translocate across the damaged intestinal barrier in portal hypertension and activate microglia via TLR4, perpetuating neuroinflammation. Ammonia synergizes with LPS and cytokines to amplify oxidative stress through mitochondrial ROS generation and impaired antioxidant defenses. Astrocytes and microglia undergo activation with morphological changes and altered metabolic function. Impaired cerebral autoregulation occurs as endothelial dysfunction develops, reducing vasodilatory reserve and making cerebral blood flow dependent on systemic arterial pressure; this is particularly dangerous in acute decompensation or sepsis. The combination of ammonia, manganese, and inflammatory mediators induces astrocytic aquaporin-4 dysregulation, contributing to cytotoxic cerebral edema (particularly critical in acute liver failure where this can rapidly progress to cerebral herniation).

• Alterations in neurotransmitter balance and neurosteroid dysfunction: Beyond GABA, there is altered metabolism of other neurotransmitters. Dopamine levels are decreased due to increased catecholamine degradation and altered synthesis, contributing to psychomotor slowing and decreased cognition. Serotonin metabolism is altered, and glutamate (the major excitatory neurotransmitter) accumulation occurs in certain brain regions due to impaired clearance. Endogenous neurosteroids (allopregnanolone and tetrahydrodeoxycorticosterone), which are GABA potentiators, are elevated in cirrhosis and may contribute to sedation. The imbalance between inhibitory (GABA, neurosteroids) and excitatory (glutamate) neurotransmission, combined with altered dopaminergic tone, produces the characteristic neuropsychiatric dysfunction of HE.

• Portal hypertension and portosystemic shunting mechanisms: The hemodynamic consequences of cirrhosis (increased intrahepatic vascular resistance and splanchnic vasodilation) create portosystemic collateral circulation. These shunts allow portal blood—containing ammonia, manganese, bacterial products, and other toxins—to bypass hepatic detoxification and enter systemic circulation directly. The degree of shunting correlates with HE risk; spontaneous portosystemic shunts (TIPS, natural varices) carry higher HE risk than preserved portal flow through a cirrhotic liver. This mechanism explains why HE can occur with relatively preserved liver synthetic function if shunting is severe (typical in TIPS-related HE), and conversely why acute liver failure causes HE despite intact initial portal flow (via ammonia accumulation due to severe hepatocyte dysfunction rather than shunting).

• Intestinal dysbiosis and bacterial translocation: The intestinal microbiota in cirrhosis is significantly altered, with increased gram-negative bacteria and urease-producing organisms, contributing to increased ammonia production. Increased intestinal permeability ("leaky gut"), due to oxidative stress, epithelial tight junction dysfunction, and altered innate immune function, allows bacterial translocation and lipopolysaccharide passage into portal circulation. This bacterial lipopolysaccharide acts synergistically with ammonia and inflammatory cytokines to amplify neuroinflammation. Dysbiosis contributes to infection risk, a major precipitant of HE.

• Hypokalemia, hyponatremia, and acid-base disturbances: Electrolyte abnormalities are important cofactors in HE pathogenesis. Hypokalemia increases ammonia production and renal ammoniagenesis (the kidney contributes significant ammonia in the setting of hypokalemia); it also impairs the Na⁺-K⁺-ATPase. Hyponatremia (whether from SIADH, diuretics, or free water retention) increases intracellular osmotic pressure and astrocytic swelling. These disturbances often precipitate or worsen HE in a previously stable patient and are critical to identify and correct.

• Cirrhosis with portal hypertension (chronic HE setting): Advanced cirrhosis of any etiology is the most common context for HE, with risk proportional to degree of hepatic dysfunction and portosystemic shunting. Alcohol-related liver disease is the most common etiology globally in developed countries, followed by hepatitis C and hepatitis B. Non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis increasingly contributes. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) result in cholestatic cirrhosis with enhanced manganese retention and HE risk. Autoimmune hepatitis with cirrhosis, Wilson disease (with acute hepatitis or chronic cirrhosis), and hemochromatosis are important etiologies to identify because they have specific treatments. Portosystemic shunting severity is a major determinant: transjugular intrahepatic portosystemic shunt (TIPS) carries HE risk in 30-50% of patients, while surgical portocaval shunts historically had high HE rates (15-40% post-procedure). The degree of shunting, not just liver synthetic function, determines HE risk; some patients with preserved INR and albumin develop HE if shunting is extensive.

• Acute liver failure (fulminant hepatic failure): Acute liver failure causes HE through severe hepatocyte necrosis and ammonia accumulation rather than shunting. Acetaminophen overdose is the leading cause in the United States and Europe. Hepatitis B (acute infection or reactivation of chronic infection in an immunosuppressed patient) is the leading cause worldwide. Hepatitis A typically causes acute HE only if there is underlying cirrhosis or if the acute infection is particularly severe. Idiosyncratic drug reactions (e.g., anti-TB drugs, NSAIDs, amoxicillin-clavulanate) can precipitate acute liver failure. Herbal hepatotoxins and Amanita phalloides poisoning are important etiologies in certain geographic regions. Autoimmune hepatitis can present with acute liver failure. Sepsis can unmask underlying cirrhosis with acute HE. Pregnancy-related liver disease (acute fatty liver of pregnancy, HELLP syndrome) causes HE in the third trimester. Recognition of the etiology is critical as some causes (acetaminophen, herpes simplex hepatitis, mushroom poisoning) have specific antidote or treatment interventions.

• Precipitating factors in chronic HE: Patients with cirrhosis often have stable neuropsychiatric function until a precipitating event triggers overt HE. Infection is the single most common precipitant (40-50% of HE episodes), including spontaneous bacterial peritonitis (SBP), bacterial pneumonia, urinary tract infection, tuberculosis, or any systemic infection triggering cytokine release. Gastrointestinal bleeding increases ammonia load substantially through blood protein catabolism and is a classic precipitant requiring urgent intervention. Renal dysfunction (acute kidney injury or worsening chronic kidney disease) reduces ammonia excretion and exacerbates HE; prerenal azotemia from diuretics, diarrhea, or sepsis is common. Hypokalemia from diuretics or diarrhea increases renal ammoniagenesis and directly worsens ammonia metabolism. Hyponatremia from SIADH, excessive diuretics, or free water retention increases astrocytic swelling. Medication non-compliance (patients discontinuing lactulose, rifaxomicin, or other HE therapies) predictably precipitates episodes. Constipation increases ammonia absorption from prolonged intestinal transit. Dehydration/hypovolemia from excessive diuretics or poor intake reduces renal perfusion and ammonia excretion. Variceal bleeding, hepatocellular carcinoma (HCC), thrombosis (portal vein, splenic vein), and portal vein thrombosis can acutely worsen shunting or liver function. Benzodiazepines and opioids directly depress CNS and precipitate HE in susceptible patients (important to avoid). Intake of high-protein diet increases ammonia load (though modern evidence suggests protein restriction is not necessary if tolerance improves with therapy). Transjugular intrahepatic portosystemic shunt (TIPS) procedure itself can precipitate HE post-intervention in up to 20-50% of cases due to increased shunting volume.

• Altered mental status and cognitive dysfunction: The hallmark of HE is impaired cognition ranging from subtle memory problems and slow information processing to frank confusion and disorientation. Patients with minimal HE have no clinically apparent alterations but show deficits on psychometric testing (digit symbol test, line tracing, reaction time tests). Overt HE presents with obvious cognitive impairment: decreased attention span, inability to concentrate, disorientation to time and place (often beginning with disorientation to time), poor insight, and inappropriate behavior. In acute HE, confusion often develops rapidly (hours to days), whereas chronic HE may develop insidiously over weeks. Patients may report subjective memory problems, difficulty with familiar tasks, or family reports of "not being themselves." In fulminant hepatic failure, progression to lethargy, stupor, and coma occurs rapidly, often associated with severe cerebral edema and brainstem herniation risk.

• Sleep-wake cycle disturbance and circadian rhythm disruption: A characteristic early finding is reversal of sleep-wake rhythm in which patients sleep during the day and remain awake at night with reduced sleep quality. This reflects altered serotonergic and dopaminergic tone and impaired circadian rhythm regulation. Insomnia, daytime somnolence, and fragmented sleep are common complaints. This finding, when present with other HE features, is highly suggestive of hepatic origin rather than primary psychiatric disease.

• Personality changes and behavioral abnormalities: Personality changes and behavioral alterations are often the first signs noticed by family members. Patients may become withdrawn, apathetic, or emotionally labile with inappropriate affect. Some become disinhibited, aggressive, or sexually inappropriate. Apathy and loss of motivation are common and may be mistaken for depression. Irritability and mood lability can occur. These changes reflect altered dopaminergic and GABAergic function and must be distinguished from primary psychiatric illness, which is challenging but important as antipsychotics may worsen HE.

• Asterixis ("flapping tremor") and neuromuscular findings: Asterixis is the pathognomonic sign of HE, defined as a coarse, irregular tremor visible when the patient extends the wrists with palms facing outward and fingers spread (wrist extension posture). It represents loss of postural stability due to impaired neuromuscular function, not true tremor, and is elicited by asking the patient to hold arms outstretched with wrists extended for 30 seconds while observing for lapses in posture ("flaps"). Asterixis is highly specific for HE but not universally present (particularly in minimal HE or very advanced stuporous/comatose stages). It may also occur in other conditions causing metabolic encephalopathy (uremia, hypercarbia, hypomagnesemia). Hyperreflexia, rigidity, spasticity, and hypertonicity can develop as HE progresses due to impaired inhibitory tone. In advanced HE, patients may develop decorticate or decerebrate posturing indicating severe cerebral dysfunction.

• Psychomotor slowing and poor coordination: Patients demonstrate obvious psychomotor slowing with slow speech, deliberate movements, and decreased spontaneity. Ataxia and incoordination may be present, reflected in difficulty with tasks like writing, drawing (patients with HE often cannot copy geometric figures or write their name clearly—a useful bedside test). Constructional apraxia (inability to perform constructional tasks) is assessed by asking the patient to draw a clock, simple shapes, or connect numbered dots; characteristic changes include poor spatial organization, tremor, and incomplete figures. Handwriting deterioration (from normal to increasingly poor quality in sequential samples) is a classic sign.

• Speech abnormalities and dysarthria: Speech becomes slurred, slow, and indistinct with reduced verbal output. Some patients develop "hepatic speech pattern" with brief pauses between words and altered cadence. Confusion may manifest as incoherent speech or word-finding difficulty.

Initial workup (exclude mimics and find the precipitant)

• Point-of-care glucose, CBC, CMP, INR: hypoglycemia, hypokalemia, hyponatremia, and AKI are both mimics and precipitants.
• Diagnostic paracentesis in any cirrhotic with ascites and encephalopathy: ascitic PMN ≥250/mm³ diagnoses spontaneous bacterial peritonitis, the classic occult precipitant. Blood/urine cultures and chest imaging complete the infection survey.
• Non-contrast head CT: cirrhotics fall and are coagulopathic — subdural hematoma is the key structural mimic. Also exclude stroke and, in the febrile patient, consider LP.
• Toxicology/medication review: benzodiazepines, opioids, and alcohol withdrawal are the leading psychoactive mimics; check thiamine status in alcohol-related disease.

Grading — West Haven criteria

• Grade I: trivial lack of awareness, euphoria/anxiety, shortened attention span.
• Grade II: lethargy, disorientation to time, obvious personality change, asterixis.
• Grade III: somnolent but rousable, gross disorientation, confusion.
• Grade IV: coma, unresponsive to pain.

Immediate stabilisation

• Airway protection: West Haven grade III–IV HE with inability to protect the airway warrants intubation and ICU care before any oral therapy — giving lactulose to an obtunded patient without a secured airway invites aspiration.
• Treat the precipitant, which is the therapy: antibiotics for SBP or other infection, transfusion plus endoscopy and octreotide for variceal bleeding, volume and albumin for AKI/hypovolemia, and correction of hypokalemia and hyponatremia. Hold diuretics and all sedatives.

First-line therapy (AASLD/EASL)

• Non-absorbable disaccharides — lactulose: the drug of choice for an episode of overt HE. Colonic bacterial fermentation acidifies the lumen, trapping NH₃ as non-diffusible NH₄⁺, and the osmotic cathartic effect purges nitrogenous substrate. Titrate to 2–3 soft stools per day, not to an ammonia level. If the patient cannot swallow safely, give as a retention enema.

Escalation / secondary prophylaxis

• Non-absorbable antibiotics — rifaximin: added to lactulose, standard dose 550 mg PO twice daily. AASLD/EASL endorse it as add-on therapy to prevent recurrence after a second episode of overt HE; it reduces urease-producing gut flora with negligible systemic absorption.
• Alternatives with weaker evidence: L-ornithine L-aspartate, polyethylene glycol, zinc repletion in documented deficiency. Neomycin and metronidazole are largely historical (ototoxicity/nephrotoxicity and neuropathy, respectively).

Definitive and procedural options

• Liver transplantation is the only definitive therapy; recurrent overt HE mandates transplant evaluation.
• Embolization of large spontaneous portosystemic shunts or TIPS reduction for refractory shunt-driven HE.

Contraindicated or obsolete

• Protein restriction: harmful. AASLD/EASL recommend maintaining daily protein intake (roughly 1.2–1.5 g/kg) to prevent sarcopenia, which itself worsens ammonia handling.
• Benzodiazepines, opioids, and antipsychotics for agitation.
• Flumazenil: transient effect only; not routine care.
• In acute liver failure, cerebral edema is managed with hyperosmolar therapy (mannitol or hypertonic saline) and urgent transplant referral, not lactulose.

Emergencies

• Cerebral edema with intracranial hypertension and uncal herniation: astrocytic glutamine accumulation drives cytotoxic swelling. This is predominantly a complication of acute liver failure with grade III–IV HE, not of chronic cirrhotic HE. Signals: systolic hypertension with bradycardia (Cushing reflex), pupillary asymmetry, decerebrate posturing, or loss of brainstem reflexes. Requires hyperosmolar therapy and emergent transplant evaluation.
• Aspiration pneumonitis/pneumonia: loss of airway reflexes in grade III–IV HE, compounded by lactulose-induced stooling and vomiting. Signals: hypoxemia, new infiltrate. Prevented by intubating before dosing enteral therapy.
• Occult precipitant left untreated — SBP, variceal hemorrhage, or a subdural hematoma masquerading as HE. Failure to improve after 24–48 hours of lactulose should trigger re-imaging and re-culturing rather than dose escalation alone.

Complications of the disease

• Recurrence and cumulative cognitive decline: each overt episode predicts further episodes and persistent deficits even after resolution.
• Covert HE morbidity: impaired driving, falls, and work disability — the reason AASLD/EASL emphasize screening despite a normal bedside exam.
• Malnutrition and sarcopenia: muscle is a major extrahepatic site of ammonia disposal via glutamine synthetase, so muscle loss creates a vicious cycle.
• Acquired hepatocerebral degeneration and hepatic myelopathy: irreversible parkinsonism or spastic paraparesis from chronic shunting and manganese deposition.
• Prognostic weight: overt HE marks decompensated cirrhosis and independently worsens survival.

Complications of treatment

• Lactulose overdose: profuse diarrhea causing hypovolemia, hypernatremia, and hypokalemia — each of which paradoxically worsens HE by increasing renal ammoniagenesis. Also ileus, abdominal distension, and rare bowel perforation with enemas.
• Neomycin: ototoxicity and nephrotoxicity. Metronidazole: peripheral neuropathy with prolonged use.
• Post-TIPS HE: increased shunt fraction; managed by shunt reduction.

• Asterixis plus sleep-wake reversal in a patient with stigmata of cirrhosis is the classic stem. Asterixis is negative myoclonus (a lapse in posture), not a true tremor, and is absent in deep coma.
• The single best next step in a cirrhotic with ascites and new confusion is diagnostic paracentesis, not another dose of lactulose. Infection — especially SBP with ascitic PMN ≥250/mm³ — is the most common precipitant. GI bleeding is the second classic trigger because hemoglobin is a nitrogen load.
• Do not order serial ammonia levels to follow therapy. AASLD/EASL state ammonia does not track severity or guide titration. The one useful negative: a normal level should make you question the diagnosis. In acute liver failure, however, a markedly elevated arterial ammonia predicts cerebral edema.
• Titrate lactulose to 2–3 soft stools daily. Mechanism: colonic acidification traps NH₃ as NH₄⁺ plus a cathartic effect. Rifaximin is add-on, not monotherapy, for preventing recurrence.
• Protein restriction is the classic wrong answer. Modern AASLD/EASL guidance maintains protein intake to preserve muscle, the body's backup ammonia sink.
• Hypokalemia is the electrolyte examiners test: it drives renal ammoniagenesis and shifts NH₄⁺ to NH₃. Correct it. Overzealous diuresis is the usual cause.
• Avoid benzodiazepines for agitation — they exploit the already-enhanced GABAergic tone. Flumazenil is a distractor: transient benefit only, not standard therapy.
• Association to know: TIPS precipitates HE in a substantial minority; refractory cases are treated by shunt reduction or embolization, and recurrent overt HE is an indication for liver transplant evaluation — the only definitive cure.
• Mimics to exclude: subdural hematoma (falls plus coagulopathy), Wernicke encephalopathy (give thiamine in alcohol-related disease), hypoglycemia, and alcohol withdrawal.